Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma (ccRCC) and investigation of circulating tumor DNA (ctDNA)

The Oncologist abstract 7 reports the same NCT03575611 ctDNA analysis as AACR CT132, with baseline MRD+ in 56% (STFS HR 2.9, 27 vs 54 months) and 3-month MRD+ STFS HR 4.3; a few clinical tallies differ slightly from CT132 and are not pooled.

The Oncologist, 2025, abstract 7 2025